RecruitingPhase 2NCT04803318
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Trametinib Combined With Everolimus and Lenvatinib in the Treatment of Recurrent/Refractory Advanced Solid Tumors: a Phase II Clinical Trial
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Enrollment
100 participants
Start Date
Jan 1, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria3
- Recurrent/Refractory advanced solid tumors
- Age between 18 and 85 years
- Expected life expectancy is greater than three months
Exclusion Criteria4
- Benign tumor
- Life expectancy is less than three months
- Serious medical commodities
- others
Interventions
DRUGCombination of three inhibitors Trametinib, Everolimus and Lenvatinib
Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04803318
Related Trials
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT0624477126 locations
64Cu-GRIP B in Patients With Advanced Malignancies
NCT058885321 location
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT0621891418 locations
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT0662577531 locations
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT0605169512 locations